Mayerle / Tilg Clinical Update on Inflammatory Disorders of the Gastrointestinal Tract

1. Auflage 2009
ISBN: 978-3-8055-9295-6
Verlag: S. Karger
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, Band 26, 226 Seiten

Reihe: Frontiers of Gastrointestinal Research

Digestive-disease-associated mortality accounts for a major part of all deaths in Western societies and inflammatory diseases such as GI infections, viral hepatitis, GERD or cancers due to chronic inflammation have a tangible economic and social impact. What further aggravates the situation is the fact that complex immunological disorders have surfaced where anti-infective treatments are not effective. Fortunately, due to breakthroughs in basic research that are being successfully translated into clinical practice, new treatment strategies are constantly evolving. In addition to the development of new therapeutic measures, however, it is also mandatory to review and periodically refine established treatment regimens to reflect current knowledge and ensure up-to-date medical care.

Autoren/Hrsg.

Mayerle, J.

Tilg, H.

Weitere Mitwirkende

Rogler, G.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Gastroentereologie, Proktologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Immunologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Infektionskrankheiten
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Hepatologie

Inhaltsverzeichnis

1;Cover;1
2;Contents;6
3;Preface;8
4;Non-Alcoholic Fatty Liver Disease;10
4.1;Abstract;10
4.2;Nomenclature;10
4.3;Epidemiology and Natural History;11
4.4;Pathogenesis;13
4.5;Clinical Features and Investigation;15
4.6;Therapy;16
4.7;Conclusions;21
4.8;References;21
5;Fibrosis in the GI Tract: Pathophysiology, Diagnosis and Treatment Options;24
5.1;Abstract;24
5.2;Cellular and Molecular Mechanisms of Fibrosis in the GI Tract;24
5.3;Liver Fibrosis;32
5.4;Pancreatic Fibrosis;33
5.5;Intestinal Fibrosis;34
5.6;Clinical Evaluation of Fibrosis Progression/Regression;34
5.7;Potential Anti-Fibrogenic Strategies;35
5.8;References;36
6;Chronic Hepatitis B: Pathophysiology, Diagnosis and Treatment Options;41
6.1;Abstract;41
6.2;Phases of Hepatitis B Infection;43
6.3;Role of Viral Load;43
6.4;Immunopathogenesis;44
6.5;Treatment Options in Chronic Hepatitis B;46
6.6;Summary;48
6.7;References;49
7;Chronic Hepatitis C: Pathophysiology, Diagnosis and Treatment Options;51
7.1;Abstract;51
7.2;Viral Cycle;51
7.3;Interferon Signalling and HCV Infection;54
7.4;Innate and Adaptive Immunity to HCV Infection;56
7.5;Progression of Fibrosis in Hepatitis C;58
7.6;Predictive Factors of Response to Treatment;59
7.7;Genome-Wide Association Studies Identified SNPs in the IL28B Region Associated with Response to Treatment;60
7.8;Molecular Signatures of Response in Liver;60
7.9;Standard of Care: Combined PEG-IFN Plus Ribavirin;62
7.10;Specifically Targeted Antiviral Therapy for HCV;62
7.11;Conclusion;64
7.12;Acknowledgment;64
7.13;References;65
8;Clinical Update on Inflammatory Disorders of the GI Tract: Liver Transplantation;68
8.1;Abstract;68
8.2;Primary Sclerosing Cholangitis;69
8.3;Autoimmune Hepatitis;74
8.4;PSC and AIH: Similarities and Differences;76
8.5;References;78
9;Hepatocellular Carcinoma;81
9.1;Abstract;81
9.2;Incidence and Epidemiology;81
9.3;Screening and Surveillance;82
9.4;Diagnosis and Staging;82
9.5;Treatment;83
9.6;Surgical Interventions for Advanced HCC;84
9.7;Locoablative Therapies with Curative Intent;86
9.8;Established palliative Therapeutic Intervention for Advanced HCC;87
9.9;Transarterial Chemoembolization;87
9.10;Drug Treatment for Advanced HCC;88
9.11;Non-Established and Experimental Treatment Options;89
9.12;References;89
10;Coeliac Disease;92
10.1;Abstract;92
10.2;Coeliac Disease, Epidemiology and Symptoms;92
10.3;Pathogenesis of Coeliac Disease;94
10.4;Genetic and Other Risk Factors;98
10.5;Oral Tolerance to Gluten;98
10.6;Intestinal Gluten Transport;98
10.7;Novel Therapies for Coeliac Disease;99
10.8;Conclusions;99
10.9;Acknowledgments;101
10.10;References;101
11;Anti-TNF Therapy in Inflammatory BowelDiseases;104
11.1;Abstract;104
11.2;Methods;105
11.3;Results;105
11.4;Conclusion;113
11.5;References;114
12;Role of Epithelial Cells in Inflammatory Bowel Disease;117
12.1;Abstract;117
12.2;Endoplasmic Reticulum Stress;118
12.3;Autophagy;120
12.4;NOD2;121
12.5;Organic Cation Transporters;122
12.6;NF?B;123
12.7;Conclusion;124
12.8;References;124
13;GI Immune Response in Functional GI Disorders;127
13.1;Abstract;127
13.2;Introduction;127
13.3;Presence of Inflammation;128
13.4;Summary;132
13.5;References;132
14;Probiotics in GI Diseases;135
14.1;Abstract;135
14.2;Probiotics;135
14.3;Inflammatory Bowel Disease;136
14.4;H. pylori Infection;139
14.5;Irritable Bowel Syndrome;140
14.6;Diverticular Disease;141
14.7;Conclusions;141
14.8;References;142
15;Microscopic Colitis;144
15.1;Abstract;144
15.2;Background;144
15.3;Epidemiology;144
15.4;Clinical Features;145
15.5;Pathophysiology;146
15.6;Treatment;147
15.7;Budesonide;147
15.8;Prednisolone;149
15.9;Bismuth Subsalicylate;149
15.10;Mesalazine with or without Cholestyramine;149
15.11;Probiotics;149
15.12;Boswellia serrata Extract;150
15.13;Antidiarrhoeals;150
15.14;Immunosuppressive Therapy;150
15.15;Surgical Therapy;150
15.16;Conclusion;151
15.17;References;152
16;Inflammatory Proteins as Prognostic Markersin Acute Pancreatitis;155
16.1;Abstract;155
16.2;Insights into Pathophysiology;156
16.3;Prediction of Severity;157
16.4;Inflammatory Proteins as Prognostic Markers;157
16.5;Conclusions;162
16.6;References;162
17;Antibiotics, Probiotics and Enteral Nutrition: Means to Prevent Infected Necrosis in AP;166
17.1;Abstract;166
17.2;Introduction;166
17.3;Antibiotics;167
17.4;Probiotics;168
17.5;Enteral Nutrition;170
17.6;Summary;172
17.7;References;172
18;IKK/NF-?B/Rel in Acute Pancreatitis and Pancreatic Cancer: Torments of Tantalus;175
18.1;Abstract;175
18.2;Transcription Factor NF-?B;176
18.3;IKK/NF-?B/Rel Pathway in Acute Pancreatitis;178
18.4;IKK/NF-?B/Rel Pathway in Pancreatic Cancer;180
18.5;Conclusion;182
18.6;References;183
19;Immunotherapy of Pancreatic Carcinoma: Recent Advances;185
19.1;Abstract;185
19.2;Immunotherapeutical Approaches;186
19.3;Summary;192
19.4;References;192
20;Helicobacter pylori Infection: To Eradicate or Not to Eradicate;195
20.1;Abstract;195
20.2;Peptic Ulcer Disease;196
20.3;Gastro-oesophageal Reflux Disease;198
20.4;Functional Dyspepsia;198
20.5;H. pylori Therapy for the Prevention of Gastric Cancer;200
20.6;MALT Lymphoma;203
20.7;Extragastric Diseases;204
20.8;Conclusions;204
20.9;References;205
21;Carcinogenesis and Treatment of Gastric Cancer;208
21.1;Abstract;208
21.2;H. pylori and Gastric Carcinogenesis;209
21.3;Inflammation, Atrophy, Metaplasia and Intestinal-Type Gastric Cancer;209
21.4;Mechanisms Linking Inflammation and Cancer;211
21.5;Molecular Alterations and Oncogenic Pathways in Gastric Cancer;212
21.6;Treatment of Gastric Cancer;213
21.7;Neoadjuvant Therapy;213
21.8;Adjuvant Therapy;214
21.9;Palliative Chemotherapy;216
21.10;References;217
22;Author Index;220
23;Subject Index;221
24;Back cover;226